Latigo Biotherapeutics, Inc. (LTGO)
NASDAQ: LTGO · Real-Time Price · USD
13.00
-0.24 (-1.81%)
Nov 20, 2026, 4:00 PM EST - Market closed
Latigo Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Commercial preparations are advancing alongside onzotrigine’s bunionectomy trial, with opioid-sparing evidence and faster onset central to its proposed differentiation. LTG-321’s chronic OA proof-of-concept readout is guided for H2 2027.
-
Onzotrigine’s bunionectomy study and the LTG-321 OA trial are both expected to read out in H2 2027. Cash of $401M is expected to fund operations into 2029.